In conclusion, our drug-targeted MR analysis demonstrated that ANGPTL3 inhibitors significantly reduce the risk of CKD, while LDLR activators are significantly associated with an increased risk of CKD. This evidence concerns the gene ANGPTL3 and chronic kidney disease.